HUDSON, Wis.--(

威斯康星州哈德逊--(

BUSINESS WIRE

商业热线

)--Molex, a parent to

)--莫仕，父母

Phillips Medisize

中等

, announced that it has completed, through an affiliate, the previously announced acquisition of Vectura Group Ltd. (Vectura) from Vectura Fertin Pharma Inc., a subsidiary of Philip Morris International Inc. Phillips Medisize is a leader in the design and manufacturing of innovative products for the pharmaceutical drug delivery, in vitro diagnostic and medtech markets.

，宣布已通过一家附属公司完成之前宣布的从菲利浦莫里斯国际公司（Philip Morris International Inc.）的子公司Vectura Fertin Pharma Inc.收购Vectura Group Ltd.（Vectura）。Philips Medisize是药物输送、体外诊断和医疗技术市场创新产品设计和制造的领导者。

With the addition of Vectura, the company now offers a wider range of formulation, device design, combination product development and manufacturing services..

随着Vectura的加入，该公司现在提供更广泛的配方，设备设计，组合产品开发和制造服务。。

The transaction includes Vectura’s proprietary technology and combination product development expertise in dry powder inhalers (DPI), including the Lever Operated Multi-dose Inhaler (LOMI) and Gyrohaler™ platforms; metered dose inhalers (MDI); nasal inhalers; and nebulizers, including the FOX™ device.

该交易包括Vectura在干粉吸入器（DPI）方面的专有技术和组合产品开发专业知识，包括杠杆操作多剂量吸入器（LOMI）和Gyrohaler™平台；计量吸入器（MDI）；鼻吸入器；和雾化器，包括FOX™设备。

Vectura also offers pharmaceutical analysis, process development, technical transfer, clinical trial supplies and regulatory services. By adding these leading capabilities, Phillips Medisize enhances its pharmaceutical R&D services and expands its capabilities in inhalation drug delivery..

Vectura还提供药物分析、工艺开发、技术转让、临床试验用品和监管服务。通过增加这些领先的能力，Phillips Medisize增强了其药物研发服务，并扩大了其吸入给药的能力。。

“Phillips Medisize will continue to expand the services we offer pharmaceutical companies thanks to the acquisition of Vectura, particularly in inhalation, to help meet growing patient needs,” said Paul Chaffin, President of Phillips Medisize. “Together Phillips Medisize and Vectura are uniquely positioned to collaborate with leading pharmaceutical customers to develop innovative products that address the growing global demand for new therapies to treat chronic respiratory diseases like asthma and COPD, as well as non-respiratory conditions.”.

Phillips Medisize总裁保罗·查芬（PaulChaffin）表示：“由于收购了Vectura，Phillips Medisize将继续扩大我们为制药公司提供的服务，特别是在吸入方面，以帮助满足不断增长的患者需求。”。“Phillips Medisize和Vectura共同拥有独特的优势，可以与领先的制药客户合作开发创新产品，以满足全球对治疗哮喘和COPD等慢性呼吸系统疾病以及非呼吸系统疾病的新疗法日益增长的需求。”。

“The Vectura team is delighted with the completion of the acquisition,” said Dr. Geraldine Venthoye, who has been appointed Chief Scientific Officer and Vice President for the Phillips Medisize Medical business. “We are excited about the opportunities and scale of Phillips Medisize, which will allow us to deliver our formulation and combination product expertise to more pharmaceutical customers as part of end-to-end pharmaceutical development.”.

杰拉尔丁·文托耶博士（GeraldineVenthoye）被任命为菲利普斯中型医疗业务的首席科学官和副总裁，他说：“Vectura团队对收购的完成感到高兴。“我们对Phillips Medisize的机会和规模感到兴奋，这将使我们能够将我们的配方和组合产品专业知识提供给更多的制药客户，作为端到端制药开发的一部分。”。

Phillips Medisize is a proven global contract development and manufacturing organization (CDMO) that designs, engineers and manufactures products for the pharmaceutical and broader healthcare industry, saving lives and improving quality of life for millions of patients annually. With the Vectura acquisition, Phillips Medisize will add approximately 350 employees to its team of more than 6,000.

Phillips Medisize是一家久经考验的全球合同开发和制造组织（CDMO），为制药和更广泛的医疗保健行业设计、设计和制造产品，每年为数百万患者挽救生命并提高生活质量。收购Vectura后，Phillips Medisize将为其6000多名员工的团队增加约350名员工。

Additionally, the team will now include more than 1,200 engineers and scientists, collaborating with customers and colleagues to deliver global design, development, formulation and manufacturing services across three continents and 30 sites..

此外，该团队现在将包括1200多名工程师和科学家，与客户和同事合作，在三大洲和30个地点提供全球设计、开发、配方和制造服务。。

“The acquisition of Vectura reflects our commitment to advancing industry-leading medical capabilities for our customers,” said Joe Nelligan, CEO, Molex, which acquired Phillips Medisize in 2016. “Together Phillips Medisize and Vectura will unlock significant growth potential to support the growing need for inhalation therapies.”.

2016年收购Phillips Medisize的莫仕公司首席执行官乔·内利根（JoeNelligan）表示：“收购Vectura反映了我们致力于为客户提升行业领先的医疗能力。“Phillips Medisize和Vectura将共同释放巨大的增长潜力，以支持对吸入疗法日益增长的需求。”。

About Phillips Medisize

关于Phillips Medisize

Phillips Medisize, a Molex company, collaborates with leading pharmaceutical, medical technology and in vitro diagnostic companies to design, engineer and manufacture life-saving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives.

莫仕公司Phillips Medisize与领先的制药、医疗技术和体外诊断公司合作，设计、设计和制造救生创新产品。Phillips Medisize是一家合同开发和制造组织（CDMO），利用其60年的专业知识和全球知名的能力，提供每年帮助数百万患者、医疗保健专业人员和个人过上更健康、更有成效的生活的产品和解决方案。

For more information, visit .

有关更多信息，请访问。

www.phillipsmedisize.com

菲利普

.

.

About Molex

关于Molex

Molex is a global electronics leader committed to making the world a better, more-connected place

莫仕是全球电子行业的领导者，致力于使世界成为一个更美好、更互联的地方

.

.

With a presence in more than 40 countries, Molex enables transformative technology innovation in the automotive, data center, industrial automation, healthcare, 5G, cloud and consumer device industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of .

Molex在40多个国家拥有业务，能够在汽车、数据中心、工业自动化、医疗保健、5G、云和消费设备行业实现变革性的技术创新。通过信任的客户和行业关系、无与伦比的工程专业知识以及产品质量和可靠性，莫仕实现了无限的潜力。

Creating Connections for Life

为生活建立联系

. For more information, visit

。有关更多信息，请访问

www.molex.com

www.molex.com

.

.